Apogee Therapeutics (APGE) Total Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has reported Total Non-Current Liabilities for 5 consecutive years, with $37.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.3 million (changed N/A YoY), while the FY2025 annual figure was $31.2 million, down 15.94% from the prior year.
• Total Non-Current Liabilities advanced to $37.3 million in Q1 2026 per APGE's latest filing, from $31.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $41.4 million in Q3 2024 and bottomed at $2.0 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $25.9 million across 5 years, with a median of $28.5 million in 2024.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 722.78% — and 2025, when it dropped 15.94%.
• Apogee Therapeutics' Total Non-Current Liabilities stood at $2.0 million in 2022, then jumped by 722.78% to $16.3 million in 2023, then jumped by 127.47% to $37.1 million in 2024, then decreased by 15.94% to $31.2 million in 2025, then grew by 19.61% to $37.3 million in 2026.
• Business Quant data shows APGE's Total Non-Current Liabilities at $37.3 million in Q1 2026, $31.2 million in Q4 2025, and $39.8 million in Q3 2025.